231 related articles for article (PubMed ID: 32449401)
1. Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice.
Koehler AB; Leung N; Call TG; Rabe KG; Achenbach SJ; Ding W; Kenderian SS; Leis JF; Wang Y; Muchtar E; Hayman SR; Hampel PJ; Finnes HD; Schwager SM; Slager SL; Kay NE; Parikh SA
Leuk Lymphoma; 2020 Oct; 61(10):2383-2388. PubMed ID: 32449401
[TBL] [Abstract][Full Text] [Related]
2. Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study.
Schwaner I; Kuhn T; Losem C; Wolff T; Otremba B; Zaiss M; Hülsenbeck J; Famulla K; Nösslinger T; Rossi D
Ann Hematol; 2024 Jun; 103(6):2013-2020. PubMed ID: 38421404
[TBL] [Abstract][Full Text] [Related]
3. Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.
Roeker LE; Fox CP; Eyre TA; Brander DM; Allan JN; Schuster SJ; Nabhan C; Hill BT; Shah NN; Lansigan F; Yazdy M; Cheson BD; Lamanna N; Singavi AK; Coombs CC; Barr PM; Skarbnik AP; Shadman M; Ujjani CS; Tuncer HH; Winter AM; Rhodes J; Dorsey C; Morse H; Kabel C; Pagel JM; Williams AM; Jacobs R; Goy A; Muralikrishnan S; Pearson L; Sitlinger A; Bailey N; Schuh A; Kirkwood AA; Mato AR
Clin Cancer Res; 2019 Jul; 25(14):4264-4270. PubMed ID: 31004001
[TBL] [Abstract][Full Text] [Related]
4. Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.
Cheson BD; Heitner Enschede S; Cerri E; Desai M; Potluri J; Lamanna N; Tam C
Oncologist; 2017 Nov; 22(11):1283-1291. PubMed ID: 28851760
[TBL] [Abstract][Full Text] [Related]
5. Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia.
Gribben JG
Br J Haematol; 2020 Mar; 188(6):844-851. PubMed ID: 31858596
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of an interdisciplinary venetoclax initiation process in minimizing risk of tumor lysis syndrome.
Cozad M; Stump SE; Buhlinger K; Collins J; Muir M; Coombs CC; Muluneh B
Leuk Lymphoma; 2022 Aug; 63(8):1831-1838. PubMed ID: 35262457
[TBL] [Abstract][Full Text] [Related]
7. Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethlators for acute myeloid leukemia.
Pelcovits A; Moore J; Bakow B; Niroula R; Egan P; Reagan JL
Support Care Cancer; 2021 Sep; 29(9):5323-5327. PubMed ID: 33661367
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax: Management and Care for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
.
Brumbaugh Paradis H; Alter D; Llerandi D
Clin J Oncol Nurs; 2017 Oct; 21(5):604-610. PubMed ID: 28945711
[TBL] [Abstract][Full Text] [Related]
9. Real-world incidence of venetoclax toxicities in British Columbia.
Lee C; Markarian A; Ladha F; Nakashima L; de Lemos M; Schaff K; Woo S; Gerrie A
J Oncol Pharm Pract; 2022 Jul; 28(5):1163-1169. PubMed ID: 35253497
[TBL] [Abstract][Full Text] [Related]
10. Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice.
Banerji V; Aw A; Laferriere N; Abdel-Samad N; Peters A; Johnson NA; Bernard MP; Gopalakrishnan S; Bull SJ; Fournier PA; Klil-Drori AJ; Hay AE; Robinson S; Owen C
Leuk Lymphoma; 2024 May; 65(5):609-617. PubMed ID: 38235709
[TBL] [Abstract][Full Text] [Related]
11. Tumor lysis syndrome: still the Achilles heel of venetoclax in treatment of CLL?
Anderson MA; Seymour JF
Leuk Lymphoma; 2020 Oct; 61(10):2286-2288. PubMed ID: 32748665
[No Abstract] [Full Text] [Related]
12. Venetoclax for the treatment of chronic lymphocytic leukemia.
Gentile M; Petrungaro A; Uccello G; Vigna E; Recchia AG; Caruso N; Bossio S; De Stefano L; Palummo A; Storino F; Martino M; Morabito F
Expert Opin Investig Drugs; 2017 Nov; 26(11):1307-1316. PubMed ID: 28972395
[TBL] [Abstract][Full Text] [Related]
13. Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.
Kater AP; Kersting S; van Norden Y; Dubois J; Dobber JA; Mellink CH; Evers LM; Croon-de Boer F; Schreurs J; van der Spek E; Visser H; Idink C; Wittebol S; Hoogendoorn M; Tonino SH; Mobasher M; Levin MD;
Blood Adv; 2018 Dec; 2(24):3566-3571. PubMed ID: 30552161
[TBL] [Abstract][Full Text] [Related]
14. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
Roberts AW; Davids MS; Pagel JM; Kahl BS; Puvvada SD; Gerecitano JF; Kipps TJ; Anderson MA; Brown JR; Gressick L; Wong S; Dunbar M; Zhu M; Desai MB; Cerri E; Heitner Enschede S; Humerickhouse RA; Wierda WG; Seymour JF
N Engl J Med; 2016 Jan; 374(4):311-22. PubMed ID: 26639348
[TBL] [Abstract][Full Text] [Related]
15. Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study.
Rogers KA; Lu X; Emond B; Côté-Sergent A; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
J Manag Care Spec Pharm; 2022 Sep; 28(9):1033-1045. PubMed ID: 35816124
[No Abstract] [Full Text] [Related]
16. Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists.
Koenig KL; Huang Y; Dotson EK; Sheredy S; Bhat SA; Byrd JC; Desmond E; Ford J; Iarocci S; Jones JA; Lucas MS; Moran ME; Wiczer TE; Woyach JA; Awan FT; Rogers KA
Blood Adv; 2020 Oct; 4(19):4860-4863. PubMed ID: 33031541
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study.
Figueroa-Mora R; Rampotas A; Halperin D; Worth T; Vidler J; Melotti D; Ferguson P; Elmusharaf N; Preston G; Furtado M; Dungarwalla M; Gohill S; Patten P; Kennedy B; Eyre TA; Schuh A; Fox CP; Munir T; Martinez-Calle N
Br J Haematol; 2023 Jul; 202(1):48-53. PubMed ID: 36951278
[TBL] [Abstract][Full Text] [Related]
18. Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.
Bouclet F; Calleja A; Dilhuydy MS; Véronèse L; Pereira B; Amorim S; Cymbalista F; Herbaux C; de Guibert S; Roos-Weil D; Hivert B; Aurran T; Dupuis J; Blouet A; Tchernonog E; Laribi K; Dmytruck N; Morel P; Michallet AS; Dartigeas C; Tournilhac O; Nguyen-Khac F; Delmer A; Feugier P; Ysebaert L; Guièze R
Ann Hematol; 2021 Apr; 100(4):987-993. PubMed ID: 33495922
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax for the treatment of patients with chronic lymphocytic leukemia.
Crombie J; Davids MS
Future Oncol; 2017 Jun; 13(14):1223-1232. PubMed ID: 28492339
[TBL] [Abstract][Full Text] [Related]
20. Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts.
Barr PM; Tedeschi A; Wierda WG; Allan JN; Ghia P; Vallisa D; Jacobs R; O'Brien S; Grigg AP; Walker P; Zhou C; Ninomoto J; Krigsfeld G; Tam CS
Clin Cancer Res; 2022 Oct; 28(20):4385-4391. PubMed ID: 35939599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]